

COMMUNITY

2024 IMPACT REPORT



The James





- 1 INTRODUCTION
- 2 LEADERSHIP GRATITUDE
- 4 PELOTONIA 2024
- **18 INNOVATIVE INITIATIVES**
- 22 COMMUNITY INSPIRES IMPACT
- 24 OSUCCC JAMES VISION
- **26 RESEARCH IMPACT**
- **40 ACKNOWLEDGMENTS**

100%

OF EVERY PARTICIPANT-RAISED DOLLAR IS DIRECTED TO INNOVATIVE CANCER RESEARCH AT THE OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER – ARTHUR G. JAMES CANCER HOSPITAL AND RICHARD J. SOLOVE RESEARCH INSTITUTE (OSUCCC – JAMES).



COMMUNITY

The powerful force inspiring impact far beyond what we could've imagined.

Pelotonia started with the brave, bold idea of people coming together to make cancer research go faster. By believing in the collective fundraising efforts of an engaged, passionate community, we would move significantly closer to seeing an end to cancer.

In 2024, the Pelotonia community came together in a big way, and there is a lot to celebrate. The incredible progress made in cancer research over the past 16 years has in large part been fueled by the tens of thousands of people who make up the Pelotonia community. Each of you has played a pivotal role.

This annual Impact Report is a collaboration between Pelotonia and the OSUCCC – James. In the following pages, you'll explore highlights from community events and innovative initiatives which inspire the philanthropy accelerating critical funds for innovative cancer research at the OSUCCC – James.

Your commitment to Ending Cancer is powering better treatments and saving lives today, and will have a lasting impact on the future.

THANK YOU.



The James

THE OHIO STATE UNIVERSITY



Dear Pelotonia Community,

This was a milestone year, crossing \$300 million raised for cancer research and continuing to impact scientific breakthroughs in ways people couldn't have imagined just 16 years ago.

PELOTONIA WAS FOUNDED ON THE BELIEF THAT, TOGETHER, WE WILL END CANCER.

The grassroots movement of Pelotonia has become a powerful force in delivering real, lasting impact. I am grateful to every single person who showed up – to ride, volunteer, fundraise, donate, and support in countless other ways. I am continually inspired by your generosity in advancing science, inspiring hope, and saving lives. As a community, we've made remarkable progress. In this annual Impact Report, we celebrate you.

Our partnership with Ohio State is at the heart of Pelotonia's mission. Collaborating with the OSUCCC – James and experts across the university, Pelotonia funds life-saving advancements in research and innovative patient care. This teamwork not only fuels progress but also the promise of what's to come as we work hand-in-hand to defeat cancer.

It enables us to fund cutting-edge research pushing the boundaries of science, while also delivering exceptional care to those facing a cancer diagnosis. From labs to clinics, this collaboration ensures the discoveries we fund reach the people who need them most, as quickly as possible. Together, we are changing lives of those impacted by cancer – not just in Ohio, but across the nation and around the world.

As a cancer survivor, this work is deeply personal to me, as I know it is to so many of you. I've witnessed firsthand the impact of Pelotonia-funded research on the lives of cancer patients, and I carry immense hope for the future. The progress we've made is inspiring, but the work ahead will be even more transformational because of your efforts. Pelotonia-funded researchers at the OSUCCC – James are tackling the most challenging and complex problems today in the cancer landscape, working tirelessly

to bring us closer to a cure. With your continued support, I'm confident today's breakthroughs will be tomorrow's cures.

I hope you'll join me in celebrating an extraordinary 2024, which was only made possible because of you. Thank you for your commitment to Ending Cancer. Together, we're building a cancer-free future.

With profound thanks.



JOE APGAR
Chief Executive Officer, Pelotonia
Cancer Survivor

The James



At The Ohio State University
Comprehensive Cancer Center –
Arthur G. James Cancer Hospital
and Richard J. Solove Research
Institute, our commitment to
eradicating cancer drives us to
develop innovative methods for
cancer prevention, screening
and treatment.

WE'RE GRATEFUL TO THE PELOTONIA

COMMUNITY and proud that 100% of every
participant-raised dollar goes to innovative
cancer research at the OSUCCC – James.



"Ride Weekend is such an inspirational event. Pelotonia's partnership is truly special because it helps fund life-saving breakthroughs in research across Ohio State and at Nationwide Children's Hospital. Those advancements make it possible to provide patients at the OSUCCC – James with world-class care while accelerating innovative treatments across the nation and around the world."

JOHN J. WARNER, MD
CEO, The Ohio State University Wexner Medical Center
Executive Vice President, The Ohio State University



"Raising over \$300 million through the 16 years of Pelotonia is remarkable. We couldn't do all that we're doing to create a cancer-free world without the support we receive from this community."

DAVID E. COHN, MD, MBA
Interim CEO and Chief Medical Officer
James Cancer Hospital and Solove Research Institute



"By harnessing the power of the Pelotonia community, the OSUCCC – James is changing the landscape of cancer care by advancing prevention, diagnosis and treatment – offering more hope for patients and families in central Ohio and beyond."

3

RAPHAEL E. POLLOCK, MD, PHD, FACS
Director, The Ohio State University Comprehensive Cancer Center
Pelotonia Board Member
Cancer Survivor

^{\$26},200,095

PELOTONIA 2024 FUNDRAISING TOTAL

12,483 **TOTAL PARTICIPANTS**

CANCER SURVIVORS



HIGH ROLLERS

6,941

RIDERS PEDALED 348.568 **MILES**

3,059

VOLUNTEERS SERVED 17.391 **HOURS**

2,483

CHALLENGERS COMPLETED 1.874

GOALS

16-YEAR **PARTICIPANTS** 1,910

FIRST-YEAR RIDERS

14-92

RIDER AGE **RANGE**





Watch the Pelotonia 2024 By the Numbers video here!





PARTICIPANTS FROM 16 COUNTRIES

(ACROSS 4 CONTINENTS)

Belaium Norway Brazil Poland Portugal Canada China Singapore Ireland Thailand Israel **United States** Malavsia United Kinadom Netherlands Vietnam

\$309,861,962

ALL-TIME PELOTONIA FUNDS RAISED SINCE 2009

for innovative cancer research at the OSUCCC - James

AN EVOLVED TAGLINE. THE SAME ONE GOAL.

ENDING CANCER



SINCE THE FIRST RIDE IN 2009, the Pelotonia community has been dedicated to a singular focus: to end cancer. This remains the mission, and the remarkable thing about Pelotonia is that it's working. The research funded by the Pelotonia community is powering significant scientific advancements and breakthrough discoveries in cancer research that are extending and saving lives.

Ending Cancer is more than a goal. It's the real, tangible progress that the Pelotonia community is fueling. This phrase is simple yet means so much. It means that we're actively doing it. It's no longer a faraway goal with an unclear path on how to get there. That's because of the unwavering commitment, tireless efforts, and uniquely compounding impact of the Pelotonia community. It's because of YOU.





Watch the Pelotonia 2024 Launch video here!













OPENING CEREMONY

AUGUST 2, 2024

Opening Ceremony is an inspirational, community-rallying party of 15,000 guests in downtown Columbus to set the tone for Ride Weekend. On stage at this year's event, Pelotonia and Ohio State leaders kicked off the evening by celebrating the community and sharing a moment of gratitude. Featured speakers included breast cancer survivor and President and CEO of The Ohio State Alumni Association, Molly Ranz Calhoun, alongside Margaret Gatti-Mays, MD, MPH, a breast medical oncologist and member of the Translational Therapeutics Program at the OSUCCC – James. The rain couldn't stop an awesome performance from Ohio-born band, Clubhouse, who concluded the event, energizing the crowd with their indie-pop music. Clubhouse has a personal connection to the Pelotonia mission as lead singer, Max Reichert, battled cancer over several years and was receiving treatment at The James. The audience could feel the joy as they performed, which was Max's last time on stage before he passed away on November 1, after a six-year fight with osteosarcoma. Now, the band is raising funds for osteosarcoma research in Max's memory.





Watch the Pelotonia 2024 Hype video here!




RIDE WEEKEND

AUGUST 3-4, 2024

Ride Weekend delivered two unforgettable days of road cycling, volunteerism, and community connection for Pelotonia's 16th signature event. More than 6,800 Riders enjoyed brand new routes ranging from 20 miles to 190 miles. Countless spectators made the experience even more memorable as they cheered, rang cowbells, and waved signs to motivate Riders as they pedaled on, with every one of the 342,770 miles they rode throughout the weekend making an impact on funding life-saving cancer research. Ride Weekend would not be possible without the valuable time and hard work of more than 3,000 Volunteers who support everything from Rider check-in. bike maintenance, and first aid to keeping rest stops stocked with pickle juice and peanut butter and jelly sandwiches and distributing medals at finish lines.



















GRAVEL DAY

SEPTEMBER 21, 2024

Gravel Day offers an adventurous cycling adventure on the scenic, gravel roads of beautiful southeast Ohio. Pelotonia's inaugural gravel ride in 2023 was enthusiastically received by participants. The second annual event increased in participation with 225 Gravel Day Riders and more than 200 Volunteers. Adding new weekend experiences this year, Gravel Day included overnight camping in tents and RVs plus a Friday Night Community Gathering to kick off the weekend with acoustic music, food, drinks, and s'mores for all to enjoy. On Saturday, Gravel Day Riders selected from 22, 30, and 52-mile looped routes, each starting and finishing at Snow Fork Event Center in Nelsonville, which featured intense climbs with total route elevation gains from 1,400 to 4,700 feet. Finish line celebrations open to participants and guests included food trucks, beverages, photo opportunities, live music, yard games, and college football on the big screen.

2024

NIGHT OF IMPACT

NOVEMBER 20, 2024

Night of Impact is a celebration of the Pelotonia community's incredible fundraising campaign. Pelotonia and OSUCCC - James leadership shared stories with attendees of breakthroughs in cancer research funded by their participation. Six individuals were also recognized as the 2024 Pelotonia Award recipients on stage. To close the evening, nine community members, including First-Year Riders, High Rollers, and Survivors as well as Pelotonia-funded Researchers and Scholars, took to the stage to flip life-sized number cards one-by-one and unveil the fundraising total. At this community gathering, we celebrated an incredible \$26,200,095 raised in 2024 - the third highest annual total in Pelotonia history – bringing all-time fundraising since 2009 to more than \$309 million. As the final number card was turned, balloons dropped from the ceiling and fireworks lit up the stage to celebrate the community's joy and progress made possible by their generosity.





Watch the Pelotonia 2024 Night of Impact program here!











2024 PELOTONIA AWARDS

Each year, we honor a handful of individuals who have gone above and beyond in their support of our mission with the Pelotonia Awards. These members of the community are champions in the fight against cancer, embodying the relentless commitment to Ending Cancer. Their personal journeys are inspiring, and their extraordinary contributions deserve to celebrated. Congratulations to the 2024 Pelotonia Award recipients!

FIRST-YEAR RIDER AWARD

This award recognizes members of the Pelotonia community who brings newfound energy, excitement, and passion to recruitment, fundraising, and participation as a First-Year Rider. This year, we honor two recipients with this well-deserved recognition.



Kyle WenkerTeam: Simply Community

Kyle Wenker's participation as a First-Year Rider was more than a physical challenge; it was a heartfelt tribute to his late wife, Megan, who passed away on Christmas Day 2023 from Stage IV lung cancer. Kyle rode 190 miles and raised \$15,765. To honor Megan, who loved cycling. Some of his fondest memories with Megan were bike rides they shared together. Her spirit lives on through Kyle's commitment to the Pelotonia mission. The support of his close and extended family made Ride Weekend even more special. Kyle's brother-in-law rode alongside him, and at the finish line, Kyle was met by his wife's family, his two young children, and a group of loved ones inspired by his passion. In Kyle's words, this was a "beautiful ode" to Megan, reflecting why Pelotonia exists: to channel grief into hope, and join a community honoring their loved ones.



Sarah Hagan Team: Designer Brands/DSW

Sarah Hagan's journey as a cancer Survivor and First-Year Rider is marked with determination and strength. Diagnosed with invasive ductal carcinoma in October 2023. Sarah faced numerous medical challenges over the next 10 months. In December 2023, she underwent lumpectomy surgery followed by an egg retrieval procedure to preserve her fertility before starting a grueling course of chemotherapy from February to May. During six weeks of radiation in June and July, Sarah continued to participate in training rides with her team, Designer Brands/ DSW, embodying the perseverance of Living Proof. On August 2 – the same day as Opening Ceremony - Sarah completed her final radiation session and was declared cancer-free. The next day, she crossed the finish line of her first 20-mile Pelotonia ride. Sarah turned her personal cancer fight into a symbol of hope and triumph, inspiring her team and the broader community.

MARY HYATT COURAGE AWARD

This award recognizes a cancer Survivor who embodies courage, perseverance, and grit, and has been instrumental in advancing the Pelotonia mission through grassroots activism, leadership, fundraising, and volunteerism.



Shirley Jordan

Shirley Jordan is a 16-Year Lead Volunteer who has played a vital role since the first year. Shirley's dedication shines through her leadership of one of the longest Ride Weekend Volunteer shifts: bike management in downtown Columbus from Friday morning through Sunday evening. Additionally, she has been a Gravel Day Lead Volunteer for two years. Despite battling her own cancer diagnosis, enduring multiple recurrences, surgeries, and treatment plans, Shirley continues to show up with an unwavering spirit. This year, just two weeks after surgery to remove a tumor, Shirley led her team of Volunteers for the entire Ride Weekend. Known for her positivity and generosity, Shirley's name frequently appears in event surveys, inspiring Volunteers to return year-after-year and with requests to be on her shifts! Shirley often brings sweet treats to staff and Volunteers, and she has raffled a handmade Pelotonia quilt to boost her individual fundraising efforts. Through it all, Shirley continually shows courage. She faces her journey as a Survivor with undeniable bravery and strength, and even as she's fought a long battle, Shirley humbly considers herself "incredibly lucky." The Pelotonia community is even luckier to benefit from her volunteerism and much more!

PELOTONIA LEGACY AWARD

This award recognizes an individual who has participated as a Rider, Challenger, or Volunteer for 10+ years, and has exhibited unparalleled leadership and passion for the Pelotonia mission.



Karl Koon
Team Buckeye

Karl Koon's 16-year dedication to Pelotonia has left an indelible mark on the community, from participants to researchers at the OSUCCC – James and more. As a longtime Rider and High Roller, Karl has personally raised more than \$110,000 for cancer research. Yet his most significant contribution has been as a 13-Year captain of Team Buckeye, Ohio State's Super Peloton that has raised nearly \$40 million in 16 years. This year, his commitment to the Pelotonia mission became even more personal when Karl was diagnosed with chronic lymphocytic leukemia (CLL) and began treatment at The James in February 2024. His chemotherapy is a pill taken twice daily called acalabrutinib, a breakthrough therapy largely developed through research by OSUCCC - James scientists and physicians with Pelotonia funding support. Karl's Pelotonia leadership and generosity have only strengthened as a cancer Survivor. As Karl enters retirement, his legacy will live on and continue to inspire Team Buckeye participants. Karl is Living Proof of the impact of scientific breakthroughs made possible by Pelotonia, and the community is grateful for his leadership.



VOLUNTEER OF THE YEAR AWARD

This award recognizes a Volunteer whose unselfish and dedicated service has made a significant difference in the Pelotonia community, demonstrating a model of commitment to our mission.



Rob McKay Lead Volunteer

Rob McKay has been an enthusiastic, reliable Lead Volunteer for nine years. He is a familiar, welcoming face to countless participants and supporters throughout Ride Weekend. As the leader of Volunteer check-in at both Opening Ceremony and the McFerson Commons start, Rob likely interacts with more Volunteers than anyone else. He has also led Volunteer check-in at Gravel Day for the past two years, demonstrating his commitment to a smooth experience for all participants. Throughout his years of service, Rob has supported many aspects of Pelotonia operations, including volunteering at the front desk, managing Volunteer check-in lists for events, leading stewardship activities and credential packing shifts at the office, attending every warehouse shift, and even supporting accounting tasks. Rob's Volunteers know how appreciated they are by the thoughtful thank you letters he sends after events. He is often providing invaluable feedback to continually enhance Pelotonia's experiences. Rob's dedication, attention to detail, and positive spirit make him an exceptional Volunteer.

PELOTONIA-FUNDED RESEARCHER OF THE YEAR AWARD

This award celebrates the incredible achievements of a Pelotonia-funded OSUCCC – James researcher. It highlights the importance of career research funding and underscores the transformative impact of the Pelotonia community's support on the work of researchers and on the lives of cancer patients.



Zobeida Cruz-Monserrate, PhD

Team Buckeye – Guts in Gear

Dr. Zobeida Cruz-Monserrate has made significant strides in advancing pancreatic cancer research with the support of Pelotonia funding. As director of the Molecular and Cellular Biology Program and Laboratory in the Division of Gastroenterology, Hepatology, and Nutrition at Ohio State, and co-leader of the Molecular Carcinogenesis and Chemoprevention Program at the OSUCCC – James, she focuses her research on pancreatic ductal adenocarcinoma (PDAC), one of the deadliest human malignancies. Since joining Ohio State in 2015, Dr. Cruz-Monserrate's lab has received more than \$350,000 from Pelotonia, funding multiple research trainees and supporting two Idea Grants to investigate the role of adipose tissue in pancreatic cancer progression. This support has been instrumental in generating preliminary data for her federally funded grant from the National Institutes of Health and National Cancer Institute. Beyond her lab's research, Dr. Cruz-Monserrate has mentored eight Pelotonia Scholars and is a nine-year Rider and Peloton Captain for Team Buckeye - Guts in Gear. Dr. Cruz-Monserrate's work is contributing to significant progress for pancreatic cancer patients, including increased survival rates. The five-year survival rate for pancreatic cancer has more than doubled since 2000.



IN COLLABORATION WITH

______ Ві







In collaboration with the OSUCCC – James, 100% of every Pelotonia Kids participant-raised dollar is directed to innovative pediatric cancer research at Nationwide Children's Hospital.

Pelotonia Kids gives children the opportunity to participate in Pelotonia experiences through both fundraising and cycling at a younger age. In 2024, Pelotonia Kids raised \$85,076!

Funds raised by Pelotonia Kids are directed to research which could improve diagnosis, treatment, and outcomes for pediatric cancer patients by leading investigators and physicians at Nationwide Children's Hospital. The OSUCCC – James has a collaborative partnership with Nationwide Children's Hospital to broaden the study of childhood cancer and accelerate the transfer of key research findings to the clinical setting. The relationship between institutions is driving novel research and developing collaborations in pediatric cancer-related studies which will also have applications to adults.











Not only does this collaboration with the OSUCCC – James and Pelotonia create a fun, new program, it will make a real difference in the lives of children. Pelotonia Kids will help accelerate Nationwide Children's groundbreaking research, making an impact on patients in central Ohio and around the world."

TIM ROBINSON

Chief Executive Officer, Nationwide Children's Hospital

"Children are among our most enthusiastic spectators and fundraisers, and this allows them to be more actively engaged participants. Pelotonia Kids is a collaboration with two of the most renowned hospitals and research centers in the U.S. We are grateful to work alongside both the OSUCCC – James and Nationwide Children's Hospital, who are leading the way in scientific research and care to save and extend the lives of cancer patients, including children."

JOE APGAR

Chief Executive Officer, Pelotonia



LAUNCHED IN MAY, there were six Pelotonia Kids rides in 2024. Prior to this launch, Pelotonia community teams have hosted youth rides as fundraising events. Four existing rides returned in 2024 within the new program, and interest in adding new Pelotonia Kids rides continues to grow!

Each Pelotonia Kids event was organized by community volunteers in partnership with Pelotonia staff. The kids rides ranged in participant ages, route layouts, and venue locations, with every Rider crossing the finish line with a big smile! Pelotonia Kids participants enjoyed finish line celebrations and received medals, t-shirts, and more.

PEDAL FOR PANCAKES, BEXLEY

Pedal for Pancakes kicked off with a morning of fun on Capital University's campus for its fifth kids ride hosted by Team Bexley and led by co-captains, Susanne Kondracke and Todd Evert. Kids ages four to 10 rode bikes and scooters, then celebrated with pancakes post-ride!





PELOTONIA KIDS UPPER ARLINGTON

Inspired by their 2-year-old's interest in "playing" Pelotonia in the backyard, Sarah Jane and Paul Germain started Pelotonia Kids Upper Arlington in 2022. Hosted at Jones Middle School, the third annual ride featured two course options to give kids of all ages and experience levels the chance to participate!





SPOKESKIDS, GRANVILLE

Aimed for older kids, SpokesKIDS engages children ages 8 to 14 in fundraising and offers a longer route in Granville. Started in 2015 by Calvin Schnaidt to honor his father David's memory, community volunteers and neighbors Kelly Clarry and Brittany Smith took over planning this Pelotonia Kids event in 2024!

PELOTONIA KIDS LINDEN

A brand-new ride, Pelotonia
Kids Linden focused on health,
safety, and the positive impact
of philanthropy for Columbus
youth. Organized by Adam Troy
and Donna Hicho with support
from Dwight Smith and additional
sponsors, the event was part
of Public Safety Week and
featured food trucks, a DJ, and
bounce houses in addition to two
routes for Linden-area youth
participants of all ages!



SPOKESKIDS JR., GRANVILLE

SpokesKIDS Jr. founder,
Nathaniel Hopping, organized
his eighth kids ride in Granville
for pre-K to third grade. In 2015,
Nathaniel wrote a letter to then
Pelotonia CEO Doug Ulman as a
five-year-old passionate about
participating in Pelotonia, which
led to the creation of this ride.
Now a 14-year-old, Nathaniel was
also a First-Year Rider in 2024!



M/I HOMES BUILDING BRIGHTER FUTURES, PLAIN CITY

Associates from M/I Homes, a Pelotonia funding partner, planned this brand-new Pelotonia Kids event in Plain City. Aimed to engage employee and neighborhood families, youth Riders rode a loop through the Darby Station community, home to one of the Pelotonia Benefit Homes, followed by a block party!

INNOVATIVE INITIATIVES



→ 2024 HIGHLIGHTS

5 Career Development Awards were granted, totaling 15 awardees since 2022.

260+ women researchers attended an interactive professional development workshop at the AACR 2024 Annual Meeting.

5 Career Development Awardees and **3 Rising Innovator Grantees** secured additional funding.

PICTURED:

Recipients of 2023 Career Development Awards and Rising Innovator Grants; Christy Tostevin, Senior Vice President of Communications and Community Relations, and Leslie Nixon, Associate Vice President of Community Relations, Victoria's Secret & Co.; and Electra Paskett, PhD, MSPH, FACE, Deputy Director for Population Sciences and Community Outreach and Founding Director of the Center for Community Outreach and Engagement at the OSUCCC – James.

BREAKING DOWN BARRIERS. EMPOWERING WOMEN. ADVANCING RESEARCH.

THE VICTORIA'S SECRET GLOBAL FUND FOR WOMEN'S CANCERS accelerates cancer research for women, by women. Through a collaborative partnership between Pelotonia and scientific partner American Association for Cancer Research (AACR), the fund offers grants to female researchers and clinicians at various career stages.

Victoria's Secret & Co., also a Pelotonia funding partner, has invested more than \$13.5 million since 2021 to foster innovation in the understanding, prevention, interception, early detection, diagnosis, and treatment of breast and gynecologic cancers with the goal of eliminating cancer health disparities and improving outcomes.

This initiative champions diverse voices to support the careers of women scientists and advance the next generation of leaders in women's cancers. Through various grants and programming, the fund supports researchers across North America, Europe, and Asia, with awardees based in the United States, United Kingdom, Spain, the Netherlands, Belgium, and China.

Five new investigators received the 2024 Career Development Awards, \$200,000 grants awarded over two years to early-stage researchers. Also new in 2024, awardees were invited to participate in the inaugural AACR Grantee Summit to facilitate connection with partners and foster collaboration among researchers.





DRIVING STRATEGIC COLLABORATION FOR BREAKTHROUGHS IN CANCER CARE



percentage of the pharmaceutical leaders and researchers at the OSUCCC – James during an event held annually leading up to Pelotonia Ride Weekend. Designed to bridge the gap between these groups, this collaboration aims to foster innovative partnerships and increase patient access to groundbreaking therapies.

The event has increased its impact significantly since the first Pelotonia Roundtable hosted in 2021, which started with four partner organizations and 45 participants.

In 2024, Pelotonia Roundtable brought together 11 industry-leading pharmaceutical organizations, including two new partners, and more than 100 participants. Representatives in research and development, patient advocacy, medical education, commercial, and other focus areas participated.

Attendees gathered on campus at The Ohio State University to engage in impactful conversations in hopes of ultimately paving the way for advancements in cancer treatment and state-of-the-art care. Discussion topics centered around enhancing access to cutting-edge clinical trials for cancer patients, bringing hope for new innovative treatment options.

"

Pelotonia Roundtable continues to provide Ohio State physician scientists and researchers with valuable connections with our corporate partners, as well as a springboard to new collaborations and research endeavors. We look forward to attending this event each summer because our Pelotonia colleagues have curated meeting agendas which are substantive and pivotal to aligning our interests with those of ourpharmaceutical partners."

REBECCA M. PETERSON, PHD

Senior Director of Strategic Initiatives, The Ohio State University Comprehensive Cancer Center







covermymeds[®]







Johnson&Johnson





sanofi

BUILDING HOPE FOR A CURE THROUGH THE GENEROSITY OF MANY



→ 2024 HIGHLIGHTS

This year, M/I Benefit Homes raised more than \$3 million for cancer research.

M/I Homes built and sold **15 Benefit Homes in 15 markets across 8 U.S. states**, including:

- · Florida: Orlando, Sarasota, Tampa
- · Illinois: Chicago
- Indiana: Indianapolis
- · Michigan: Detroit
- Minnesota: Minneapolis
- · North Carolina: Charlotte, Raleigh
- Ohio: Cincinnati, Columbus
- · Texas: Austin, Dallas, Houston, San Antonio

M/I HOMES BENEFIT HOMES PROGRAM engages company leadership, associates, partners, vendors, and distributors across the country through what the organization does best. Homebuilders aim to make dreams come true for their homeowners, and M/I Homes has transformed this concept by donating proceeds from the sale of each Benefit Home to Pelotonia, accelerating life-saving cancer research at the OSUCCC – James.

M/I Homes, also a Pelotonia funding partner, introduced this one-of-a-kind corporate philanthropy initiative in 2022. By expanding to new markets and involving associates across the company and through their professional network, M/I Homes' creativity and generosity continues to make an impact.

In 2024, M/I Homes committed to building 15 Benefit Homes across the nation. Every home sold, contributing more than \$3 million to Pelotonia. To date, M/I Homes has sold 45 Benefit Homes in 15 markets to raise critical funds for cancer research.

Since 2014, M/I Homes has raised more than \$10 million for Pelotonia.

Corporate partnerships like this leverage a company's business niche in an innovative way to further its philanthropy. By engaging partners to support with donating labor, materials, and more, M/I Homes exemplifies how a collective community can achieve more than ever thought possible.





INSPIRING LEADERS TO SOLVE SEEMINGLY UNSOLVABLE PROBLEMS



RTRX REDEFINES THE CONFERENCE

EXPERIENCE. Held annually in Columbus, Ohio, in partnership with Ride Weekend, this four-day immersive leadership experience convenes attendees from startups to Fortune 500 companies.

RTRX was founded in 2012 by Rockbridge and has grown through a partnership between Rockbridge, Pelotonia, and the Columbus Partnership. RTRX primes optimists for action and believes that together, we can solve seemingly unsolvable problems. One hundred percent of RTRX proceeds benefit Pelotonia, with more than \$7.2 million invested to date.

RTRX 2024 focused on our ability to *shape tomorrow* to solve problems and create a world full of hope,

curiosity, and conversation. Programming featured world-class speakers through mainstage keynotes and masterclass workshops.

Pelotonia CEO Joe Apgar and Anil Parwani, MD, PhD, MBA, professor and chair of the Department of Pathology at The Ohio State University College of Medicine, delivered a keynote celebrating the impact of Pelotonia funding on cancer research breakthroughs and the future of detection and treatment through digital pathology.

Attendees also enjoyed a "Leadership Lessons" masterclass moderated by Pelotonia Vice Chair Doug Ulman with former Ohio State head football coach Jim Tressel.


→ 2024 HIGHLIGHTS

Nearly 1,000 RTRX attendees came from **377 companies and across 28 U.S. states**, and included various levels of experience, from college students to CEOs.

Keynote speakers included **experts, innovators, and changemakers** in their field, including: Tucker Bryant, Jimmy Chin, Michelle Gethers, and Damon West.

A **curated selection of masterclasses** offered hands-on workshop sessions on leadership, AI, personal branding, managing stress, and more.

Within the RTRX Super Peloton, RTRX's HI-Impact Campaign engaged 46 hotel properties across the country to **raise \$315,000** for cancer research.







By investing in cutting-edge research, you're helping us accelerate clinical trials that lead to groundbreaking therapies. Our focus on recruiting top talent and funding promising ideas is inspiring the next generation of researchers and advancing technology that is aimed at saving lives and providing hope.

With the help of funding from the Pelotonia community, we're able to pursue our shared vision of creating a cancer-free world — one person, one discovery at a time.

The James



Dear Pelotonia Community,

Pelotonia's momentum grows stronger each year as we strengthen our collective efforts to raise money for cancer research that translates to innovative lifesaving treatments.

FOR 16 YEARS, this special community has partnered with Ohio State's cancer program, and it continues to be unmistakably transformational.

The millions of dollars raised by Pelotonia Riders, Challengers, Volunteers and Donors has led to advancements in preventing, detecting, diagnosing and treating this disease in its many forms.

The stories and numbers in this impact report reflect the difference your commitment has made by raising an incredible amount of money—with every participant-raised dollar going directly to cancer research thanks to Pelotonia's funding partners.

Our Idea Grants program exemplifies Pelotonia's impact. This report highlights three groundbreaking research projects that likely wouldn't have been possible without support from Pelotonia.

However, thanks to Pelotonia investment, these researchers were able to gather sufficient data to apply for and receive additional outside funding from sources such as the National Cancer Institute.

I extend my gratitude to the Pelotonia community for supporting my colleagues' and my research, and for helping to extend my time in this world. In 2017, I was diagnosed with chronic lymphocytic leukemia and am thankful there is a drug I can take that was largely developed at Ohio State with Pelotonia funding.

The money you have raised has directly impacted thousands like me. I thank you personally and professionally for providing hope for so many, and I look forward to continuing to pursue our shared vision of a cancer-free world

Sincerely,



RAPHAEL E. POLLOCK, MD, PHD, FACS Director, The Ohio State University Comprehensive Cancer Center Pelotonia Board Member Cancer Survivor

RESEARCH IMPACT

The James



RECRUITING THE BRIGHTEST MINDS

The OSUCCC – James continuously works to bring the brightest minds in cancer research to Ohio State. We're highlighting three of our renowned researchers who bring expertise in immunotherapy, drug development and clinical trials, which are all critical on the journey to a cancer-free world.





Discover how Dr. Barber is building on groundbreaking discovery that may lead to new treatments for cancer and inflammation.



Read more about Dr. Tsai's experience and expertise she brings to Ohio State.



Find out more about Dr. Rolfo's specialized knowledge and contributions to oncology.



CHRISTIAN ROLFO, MD, PHD, MBA, DR.HC.,

a highly respected cancer researcher and physician, joined Ohio State as director of the Division of Medical Oncology and associate director for early-phase clinical trials at the OSUCCC – James.

Dr. Rolfo is recognized for leadership in establishing guidelines for liquid biopsy in oncology, which reflects advancements such as the "plasma first" versus "tissue first" approach for molecular testing in advanced non-small cell lung cancer. He also has helped develop such targeted therapies as entrectinib and selpercatinib.

His recruitment from the Mount Sinai Icahn School of Medicine in New York is a significant addition to Ohio State's mission of advancing cancer research and patient care.



SUSAN TSAI, MD, MPH, is a recognized leader in gastrointestinal oncology with a focus on pancreatic cancer. Her research primarily involves blood-based biomarkers and precision medicine clinical trials for patients with this disease.

She has led several investigator-initiated clinical trials in the presurgical setting, including a groundbreaking trial that used molecular profiling to guide chemotherapeutic selection.

Dr. Tsai came to Ohio State from the Medical College of Wisconsin to direct the Division of Surgical Oncology in the Department of Surgery and is also in the Translational Therapeutics Program at the OSUCCC – James.





GLEN BARBER, PHD, FRS, focuses his acclaimed research on how cells detect and respond to infections, and he has pioneered the use of viruses as cancer therapeutics and vaccines. Dr. Barber serves as director of the Center for Innate Immunity and Inflammation in the OSUCCC – James Pelotonia Institute for Immuno-Oncology (PIIO). You can read more about the latest happenings in the PIIO later in this report.

Dr. Barber is one of three recipients of the 2025 Paul Ehrlich and Ludwig Darmstaedter Prize, Germany's highest medical award, for outstanding contributions to research in hematology, immunology or chemotherapy. He was recruited from the University of Miami (Florida).



RESEARCHER DEVELOPMENT

SINCE 2010

The cancer program has recruited over

290

top scientists with Pelotonia support.

The James



FUNDING INNOVATIVE IDEAS

Pelotonia-funded Idea Grants are research projects that help teams of faculty researchers at Ohio State gather early data for cutting-edge ideas so they can later apply for larger funding from such external sources as the National Cancer Institute.

This program has allowed the OSUCCC – James to fund hundreds of faculty-led pilot research projects across 11 colleges and Nationwide Children's Hospital.

-



Explore the innovative CAR T-cell therapy trial and the promise it holds for certain patients.



Read more about Dr. Cruz-Monserrate and her team's innovative work.



Take a closer look at this groundbreaking study on treating brain cancer.

MAKING A REAL DIFFERENCE

Zobeida Cruz-Monserrate, PhD, focuses her research on pancreatic cancer, a devastating diagnosis, but thanks to the Pelotonia community there's hope.

Dr. Cruz-Monserrate's research regarding possible links between body fat and pancreatic cancer received early support from the Pelotonia community. This allowed her and her lab team to generate the data needed to propel the research forward.

She has since been awarded a five-year, \$3.53 million grant from the National Cancer Institute.





TESTING A NEW THERAPY DEVELOPED AT OHIO STATE

Support from Pelotonia funding paved the way for OSUCCC - James researchers to receive a five-year, \$3.04 million grant from the National Cancer Institute to study a new cancer treatment for patients with relapsed or treatment-resistant B-cell cancers.


Sumithira Vasu, MBBS, Lapo Alinari, MD, PhD, and Marcos J. de Lima, MD, are principal investigators of this first-in-human, phase I clinical trial, which is testing an in-house manufactured CAR T-cell therapy that targets three proteins simultaneously instead of just one in patients with B-cell lymphomas and B-cell leukemias.

FUNDING A BREAKTHROUGH STUDY OF BRAIN CANCER TREATMENT

Treating glioblastoma, the deadliest type of brain cancer, is challenging because the brain has a natural barrier that blocks cancer drugs, and these cells quickly become resistant to treatments.

However, researchers at the OSUCCC – James have discovered that combining the brain-penetrating antipsychotic drug pimozide along with a drug that inhibits glutamine metabolism called CB-839 can overcome this resistance and slow down the growth of glioblastoma tumors.

The research team, led by Deliang Guo, PhD, believes that their findings will have a significant and lasting impact across many areas, including and treatment models.





IDEA GRANTS

SINCE 2010

221 grants worth **\$31.35 million**

CURRENT (2024)

11 new Pelotonia-funded Idea Grants totaling \$1.4 million

The James



ADVANCING NEW WAYS OF PREVENTION AND DIAGNOSIS

The OSUCCC – James allocates funding to purchase sophisticated equipment and invests in statewide initiatives.

Keeping up with modern advances in technology helps researchers discover better ways to treat or prevent cancer. Statewide initiatives promote early detection and better outcomes for colorectal, uterine, lung and breast cancer patients in Ohio.






Dive into all of the technology acquisitions.



Understand more about the Turning the Page on Breast Cancer initiative.





SOPHISTICATED SLIDE SCANNER AIDS CANCER RESEARCHERS

Among the equipment purchases supported by Pelotonia funds was an Olympus VS200 Research Slide Scanner for the Comparative Pathology and Digital Imaging Shared Resource.

The new slide scanner enables scientists to capture high-resolution images for improved analysis. This resource assists OSUCCC – James researchers who use animal models to study human disease. It's also useful for translational studies that use human tissue obtained for research.



Black women are more likely to develop aggressive breast cancers and have a 42% higher death rate compared to white women. A statewide initiative by the OSUCCC – James, partially funded by Pelotonia, is proving effective in addressing these disparities.

The "Turning the Page on Breast Cancer" initiative started in 2021 and is led by Electra Paskett, PhD, MSPH, FACE. It targets 11 Ohio counties with high breast cancer rates among Black women.

The initiative improves local health care facilities' breast cancer screening, follow-up and treatment; involves community organizations and social media to raise awareness; and provides education and personal risk information through a culturally relevant website.



"The money that has been raised by Pelotonia has helped so much toward finding ways to detect cancer early and prevent it. You can't imagine the number of people who are benefiting from the research being done, not only across Ohio, but around the nation and the world."

ELECTRA PASKETT, PHD, MSPH, FACE

Deputy Director for Population Sciences and Community Outreach and Founding Director of the Center for Community Outreach and Engagement at the OSUCCC – James







INSTRUMENTS OF DISCOVERY AND STATEWIDE INITIATIVES

CURRENT (2024)

\$488,000

for the purchase of sophisticated equipment for some of the cancer program's Shared Resources, which provide specialized services to cancer researchers

4

statewide initiatives funded by Pelotonia

The James



4



Learn more about this therapeutic agent discovered at Ohio State.



Explore proton therapy for cancer treatment.

DELIVERING NEW THERAPIES THAT GIVE HOPE

Pelotonia dollars support OSUCCC – James initiatives such as the Drug Development Institute, digital pathology, the Total Cancer Care® protocol, the Center for Cancer Engineering and Cures, and proton therapy. These strategic research investments are helping OSUCCC – James researchers make a difference.

OHIO STATE DRUG DISCOVERY ENTERS CLINICAL TESTING

A therapeutic agent discovered and developed at Ohio State will soon be used for cancer treatment at patient bedsides as part of a phase I, first-in-human clinical trial available only at the OSUCCC – James.

Jabez Biosciences is the industrial development partner for this oral drug, now known as JBZ-001. The drug targets cancer by stopping a key enzyme, dihydroorotate dehydrogenase (DHODH), which enables cancer to grow and spread.

The trial will test a DHODH inhibitor discovered, fully developed and moved toward commercialization at Ohio State. Asrar Alahmadi, MBBS, of the Translational Therapeutics Program at the OSUCCC – James, is principal investigator. Funding from Pelotonia and other philanthropy enabled the drug development that led to the trial, which will first enroll patients with solid tumors and non-Hodgkin's lymphoma.



"We are introducing a best-in-class drug that we believe holds tremendous potential to help patients who have limited effective treatment options. It is such an incredibly exciting development."

CHAD BENNETT, PHD

Senior director of chemistry for the Drug Development Institute at the OSUCCC – James, and co-lead investigator of the research team that developed this new drug



CENTRAL OHIO'S FIRST PROTON THERAPY CENTER

Nationwide Children's Hospital and the OSUCCC – James have opened a \$100 million, 55,000-square-foot Proton Therapy Center. This state-of-the-art facility offers highly targeted radiation therapy for treating complex tumors.

Proton therapy uses protons instead of X-rays to destroy cancer cells. Its precision minimizes damage to surrounding healthy cells, a common side effect of conventional radiation therapy.

The Proton Therapy Center offers comprehensive radiation oncology treatment options for both adult and pediatric patients at a single location. The center, which aims to improve cancer care accessibility and outcomes for patients in central

Ohio and beyond, houses the latest and best machines for delivering proton therapy.

Vital components of these machines were pioneered in the lab of Arnab Chakravarti, MD, chair of the Department of Radiation Oncology at Ohio State, who is widely known as one of the world's leading experts in proton therapy. At the time of this publishing, Ohio State is the first and only facility in the world with this latest technology.

The center is also equipped to conduct research on an experimental high-dose proton therapy called FLASH that can target treatment to a pinpoint and deliver it in a 10th of a second. Ohio State is one of just a few institutions in the world poised to study this exciting therapy.





STRATEGIC RESEARCH INVESTMENT: PROTON THERAPY CENTER

SINCE OPENING IN DECEMBER 2023

 $\begin{array}{c} \textbf{Approximately} \\ \textbf{100} \\ \textbf{patients treated to date} \end{array}$

states from which patients have been treated

2,300 treatments delivered

The James



INSPIRING THE NEXT GENERATION OF CANCER RESEARCHERS

The OSUCCC – James annually awards \$2 million in Pelotonia funds to train the next generation of cancer researchers. The awards are issued to Ohio State students in any discipline or level who want to conduct cancer research in the labs of faculty mentors.


4



Better understand the Pelotonia Scholars Program at the OSUCCC – James.



Learn more about the first Mason Fisher Grant.



SCHOLARS SPOTLIGHT

"The Pelotonia Postdoctoral Scholarship Award I received during my fellowship at Ohio State helped me gain the experience and skills I needed to transition to an independent clinical/translational physician scientist and learn how to collaborate with other investigators to foster impactful research to help patients with cancer diagnoses.

Today, my research focuses on developing new therapies and treatments for patients with acute myeloid leukemia and other myeloid malignancies. I'm proud to still be conducting my research at Ohio State and contributing to the work we do in pursuit of a cancer-free world."

ALICE MIMS, MD

Co-Leader of the Leukemia and Hematologic Malignancies Program at the OSUCCC – James





COTTINI AWARDED INAUGURAL MASON FISHER GRANT

Francesca Cottini, MD, assistant professor in the Division of Hematology and member of the Translational Therapeutics Program at the OSUCCC – James, is the first recipient of the Mason Fisher Grant. Funded 100 percent with Pelotonia dollars, the Mason Fisher Grant Program provides early-career researchers in Ohio State's College of Medicine or the OSUCCC – James with up to \$50,000 to advance their research of genetic mutations that can lead to cancer.

Dr. Cottini will use these grant dollars to study why patients with myeloma are at a higher risk of developing a second blood cancer, such as acute leukemia or myelodysplastic syndrome.

The grant program honors Mason Fisher, an Ohio State medical student who passed away experiencing a medical event while he was riding in the 2022 Pelotonia. Mason, who wanted to be a cancer surgeon-scientist, was a passionate advocate for research and rode in Pelotonia for three years.





PELOTONIA SCHOLARS PROGRAM

32 scholarships were awarded in 2024

THOSE SCHOLARS INCLUDE

13 undergraduate students

14 graduate students

3 postdoctoral researchers

2 medical students

SINCE 2010

The Pelotonia Scholars
Program has awarded **712 scholarships** to students
from 53 countries and 36
U.S. states.

The James



TRANSFORMING CANCER CARE

PELOTONIA INSTITUTE FOR IMMUNO-ONCOLOGY (PIIO)

In its first five years under the leadership of Founding Director Zihai Li, MD, PhD, the PIIO – established in 2019 through an initial pledge of \$102 million from the Pelotonia community – has recruited 31 top-tier faculty researchers, bringing the total number of PIIO faculty to 124 scientists who drive breakthroughs in immuno-oncology, a discipline that harnesses the body's immune system to combat cancer.

7



Further explore the bladder cancer study in the journal *Nature*.



Learn more about the promise of this cell therapy.



Dive deeper into the immunotherapy treatment for breast cancer Dr. Gatti-Mays is researching.

NEW CELL-BASED IMMUNOTHERAPY OFFERS HOPE FOR PATIENTS WITH METASTATIC LUNG CANCER

Researchers at the OSUCCC – James' PIIO say a new cell therapy, lifileucel, could be a promising potential treatment for patients with Stage 4 lung cancer – specifically for patients who were previously treated but later developed resistance to other therapies.

In the first global phase II clinical trial of the drug lifileucel in lung cancer, oncologists led by Kai He, MD, PhD, showed the approach was safe and effective in treating metastatic non-small cell lung cancer, the most common type of lung cancer.

This therapy uses a patient's own white blood cells, which are extracted from a tumor through surgery and grown in numbers in a lab to become more robust for fighting cancer before being returned to the patient. The results of the phase II clinical trial were published in the journal *Cancer Discovery*.



PIIO RESEARCHERS STUDY SEXUAL DIMORPHISM IN T-CELL EXHAUSTION AND BLADDER CANCER

Bladder cancer disproportionately affects men, with a prevalence 3-5 times higher than in women even after adjusting for factors like smoking.

Researchers in the OSUCCC – James' PIIO and Cedars-Sinai Medical Center are studying how biological differences between sexes impact bladder cancer to improve treatments. The project, led at Ohio State by Zihai Li, MD, PhD, involves three leading laboratories specializing in immunology, cancer biology/functional genomics, and epigenetics.

The researchers recently published a study in the journal *Nature* which revealed that tumors without the Y chromosome correlate with poor prognoses but are potentially more responsive to PD-1-targeted immunotherapy.

The collaborative effort highlights the importance of understanding sex-specific factors in cancer biology and underscores the potential for targeted interventions to improve patient outcomes.





"The way I look at cancer treatment today, especially in the metastatic setting, is that it's a marathon.

When you have a person in front of you and you know their family, friends and their story, there's no better motivator to push through and do the things that are outside the box."

MARGARET GATTI-MAYS, MD, MPH

Associate Professor in the Division of Medical Oncology at Ohio State

Member, Translational Therapeutics Program, OSUCCC - James



PELOTONIA INSTITUTE FOR IMMUNO-ONCOLOGY

SINCE 2019

124 members awarded **\$43M** in annual grant funding (\$25M from NCI)

254 Immunotherapy Clinical Trials launched

CURRENT (2024)

12 new members

4 new recruits

32 new grants, \$5M in annual grant funding (\$3.6M from NCI)

206 peer-reviewed articles

THANK YOU FOR YOUR UNWAVERING SUPPORT

When you support Pelotonia, you join a community dedicated to creating a cancer-free world, empowered by scientific cancer research at the OSUCCC – James. Since 2010 the cancer program at Ohio State has been making advancements in preventing, diagnosing and treating this disease – but there is still work to be done.

Thank you for your continued trust and partnership. Together, a cancer-free world is within reach.



SINCE 2010

Recruited over

290 top scientists

CURRENT (2024)

3 more acclaimed researchers



SINCE 2010

221 grants worth\$31.5 million

CURRENT (2024)

11 new Pelotonia-fundedIdea Grants totaling\$1.4 million







INSTRUMENTS OF DISCOVERY AND STATEWIDE INITIATIVES

CURRENT (2024)

\$488,000

for the purchase of sophisticated equipment for some of the cancer program's Shared Resources, which provide specialized services to cancer researchers

4

statewide initiatives funded by Pelotonia



PELOTONIA SCHOLARS PROGRAM

SCHOLARSHIPS AWARDED:

712 32

UNDERGRADUATE STUDENTS:

316 13

GRADUATE STUDENTS:

222 14

222 14

POSTDOCTORAL RESEARCHERS:
158 3

MEDICAL STUDENTS:
16 2



PELOTONIA INSTITUTE FOR IMMUNO-ONCOLOGY (PIIO)

SINCE 2019

124 members awarded **\$43M** in annual grant funding (\$25M from NCI)

254 Immunotherapy Clinical Trials Launched

CURRENT (2024)

12 new members

4 new recruits

32 new grants, \$5M in annual grant funding (\$3.6M from NCI)

39

206 peer-reviewed articles

2024 IMPACT REPORT

THANKS TO OUR GENEROUS FUNDING PARTNERS, PELOTONIA IS ABLE TO DIRECT 100% OF EVERY PARTICIPANT-RAISED DOLLAR TO INNOVATIVE CANCER RESEARCH AT THE OSUCCC – JAMES.

BENEFITING

The James



MAJOR FUNDING PARTNERS



Bath&BodyWorks®



PEGGY & RICHARD SANTULLI



SUPPORTING FUNDING PARTNERS









NOTABLE FUNDING PARTNERS





DIAMOND HILL









LEAVING A LASTING IMPACT ON ENDING CANCER

THE PELOTONIA LEGACY SOCIETY is a group of forward-thinking supporters who share a vision to provide for future generations of cancer patients and their families.

These individuals have made a lasting commitment to the fight against cancer by including Pelotonia in their estate plans. As part of the Pelotonia Legacy Society, you will join this group of like-minded individuals who are dedicated to the longevity of our mission.

Consider joining these generous community members in their ongoing commitment to Ending Cancer by making a planned gift and becoming part of the Pelotonia Legacy Society.



"I simply want an end to cancer and I firmly believe that the only way to do that is to provide research funding to the best and brightest researchers so that we one day get to experience a life that is cancer-free."

KATHY QUICKERT

10-Year Rider, High Roller, and Peloton Captain for Team Lane Bryant



"My mom was my inspiration. After we lost my dad to cancer, she felt strongly about including Pelotonia in her updated will. When she passed away this spring and I reevaluated my estate plans, I wanted to do the same."

SARAH BUCKLEY

13-Year participant as a long-time Lead Volunteer and Challenger





Learn more about planned giving.

2024 IMPACT REPORT 41

→ PELOTONIA BOARD



Robert H. Schottenstein

BOARD CHAIR

CHAIRMAN & CEO

M/I Homes, Inc.



Doug Ulman
VICE CHAIR
SENIOR ADVISOR TO
THE PELOTONIA CEO



Carol R. Bradford
MD, MS, FASC
DEAN, COLLEGE OF MEDICINE
& VICE PRESIDENT
FOR HEALTH SERVICES
Wexner Medical Center



Renee Cacchillo
PRESIDENT & CEO
Safelite® Group



Victor Crawford BOARD MEMBER The Hershey Company



Cindy Hilsheimer
MANAGING PRINCIPAL
BeecherHill



Peter J. Mohler PHD

EXECUTIVE VICE PRESIDENT
FOR RESEARCH, INNOVATION
AND KNOWLEDGE
The Ohio State University



Raphael Pollock MD, PHD

DIRECTOR

The Ohio State University
Comprehensive Cancer Center



Daniel Rosenthal
PRESIDENT & CEO
Global Critical Logistics



Steve Steinour
CHAIRMAN, PRESIDENT & CEO
Huntington Bancshares Inc.



Abigail Wexner
CHIEF EXECUTIVE OFFICER
Whitebarn Associates



→ PELOTONIA TEAM



Jackie Adler MARKETING & COMMUNICATIONS COORDINATOR



Ashley Ellashek MERCHANDISING SPECIALIST



COMMUNITY ENGAGEMENT



Joe Apgar CHIEF EXECUTIVE OFFICER



Jess Audey TECHNOLOGY SERVICES



Carolyn Appelhans COMMUNITY ENGAGEMENT DIRECTOR



GIFT PROCESSING MANAGER



Nick Denby CHIEF FINANCIAL OFFICER



Lauren Graham **EVENT OPERATIONS** DIRECTOR



Callan Hash EXECUTIVE ADMINISTRATOR



Grace Jenkins GIFT PROCESSING COORDINATOR



Eric Olsavsky COMMUNITY ENGAGEMENT & PARTNERSHIPS VICE PRESIDENT



Maddie Parisi EVENT & VOLUNTEER OPERATIONS COORDINATOR



Hannah Rose COORDINATOR



Brandon Simpauco MARKETING &
COMMUNICATIONS
MANAGER



Alexa Waldron PARTNERSHIP EXPERIENCE COORDINATOR



Erika Walker PHILANTHROPY AND STEWARDSHIP MANAGER



Katie Wilson MARKETING & COMMUNICATIONS DIRECTOR



Colin Wright EVENT & VOLUNTEER OPERATIONS COORDINATOR

2024 IMPACT REPORT 43

COMMUNITY

Pelotonia would not be possible without you.

EVERY MILE YOU RIDE IS FURTHERING THE MISSION.

Every hill you climb is worth the effort.

Every shift you volunteer makes a difference.

Every single dollar you raise is improving the lives of patients.

Every story you share inspires others to join this movement.

Every one of you is making an impact.

You are investing in the next big ideas. You are funding the next generation of great scientists. You are bringing groundbreaking cancer research to life.

On behalf of Pelotonia and OSUCCC - James,

THANK YOU

for your generosity and commitment to our mission.



PELOTONIA°



OPENING CEREMONY AUGUST 1 RIDE WEEKEND AUGUST 2-3 GRAVEL DAY OCTOBER 4

REGISTRATION OPENS MARCH 5

MAKE AN IMPACT. SAVE LIVES.

Join the Pelotonia community to accelerate innovative cancer research at the OSUCCC – James.



REGISTER OR DONATE AT PELOTONIA.ORG



